A.I. tools are increasingly used in human resources activities. Onamica Dhar, Economist at PRINTING United Alliance, shares ...
TURKU, FI / ACCESS Newswire / March 27, 2025 /Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potential TURKU, FINLAND - Faron ...
New Year is celebrated on 1 January all over the world. Annual New Year and Financial Year start on different days in every ...
The fireworks soaring beyond the right-field wall over the view of the Tower Bridge and downtown Sacramento skyline were ...
Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...
An employee, who had thorough plans of enjoying a family holiday, served a lesson in work-life balance to an overly demanding ...
Alight's stock dip signals opportunity as management emphasizes free cash flow, cloud migration, and AI boosts. Explore the ...
Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.
Altis's AI Model Outperforms RECIST 1.1 in Predicting Overall Survival These findings showcase IPRO-Δ's potential to accelerate clinical d ...
Despite the randomized trial showing a difference in outcomes, more data are needed before changing practice, says one expert ...
TURKU, FI / ACCESS Newswire / March 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potentialTURKU, FINLAND - Faron P ...
Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...